Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2025)
Autolus Therapeutics (AUTL) posted quarterly EBIT Margin of 298.35% for Q4 2025, up 26130165.0% year-on-year from N/an in Q4 2024, and up 11.71% on a QoQ basis from 337.93% in Q3 2025.
Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported EBIT Margin for 9 consecutive years, with 298.35% the latest figure, recorded in Q4 2025.
- Quarterly EBIT Margin rose 26130165.0% year-over-year to 298.35% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 358.87% (up 202464.0% YoY) and the FY2025 annual result came in at 358.87%, up 202676.0% from the prior year.
- EBIT Margin grew to 298.35% in Q4 2025 per AUTL's latest filing, from 337.93% in the prior quarter.
- Over the last five years, EBIT Margin for AUTL reached as high as 292.58% in Q2 2025 and fell as low as 261600.0% in Q4 2024.
- A 5-year average of 23953.96% and a median of 2039.84% in 2021 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin plunged 899125 bps — and 2025, when it jumped 26130165 bps.
- Year by year, EBIT Margin stood at 17099.58% in 2021, then soared by 98 bps to 318.39% in 2022, then sank by 3219 bps to 10567.73% in 2023, then plunged by 2375 bps to 261600.0% in 2024, then jumped by 100 bps to 298.35% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 298.35%, 337.93%, and 292.58% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -298.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -298.35% |
| Sep 30, 2025 | -337.93% |
| Jun 30, 2025 | -292.58% |
| Mar 31, 2025 | -726.34% |
| Dec 31, 2024 | -261,600.00% |
| Mar 31, 2024 | -383.73% |
| Sep 30, 2023 | -10,567.73% |
| Mar 31, 2023 | -3,030.03% |
| Dec 31, 2022 | -318.39% |
| Sep 30, 2022 | -1,576.49% |
| Mar 31, 2022 | -21,798.80% |
| Sep 30, 2021 | -17,099.58% |
| Jun 30, 2021 | -2,503.19% |
| Mar 31, 2021 | -14,822.30% |
| Dec 31, 2020 | -11,715.35% |
| Sep 30, 2020 | -9,750.68% |
| Jun 30, 2020 | -13,496.25% |
| Mar 31, 2020 | -11,409.17% |
| Jun 30, 2019 | -2,926.24% |
| Mar 31, 2019 | -1,535.49% |